CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 351 enrolled
Drug / intervention
Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin +1 moredrug
Likely dose
Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin 120 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02503865
NCT02503865Phase 2Completed
CompareCT.gov

Phase 1-2 Study of Development of Rational Ways of Medical and Non-medical Treatment Methods for Metabolic Syndrome

Nazarbayev University·interventional·Posted Jul 21, 2015·Updated Nov 30, 2015

In Brief

A Phase 2 clinical trial evaluating Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin and "Analimentary detoxication" for Metabolic Syndrome. Completed, enrolled 351 participants across 1 site.

Detailed Summary

Metabolic syndrome: aetiology, pathogenesis, diagnosis, clinical management and prognosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesKazakhstan
CollaboratorsInstitute Of Cardiology & Internal Diseases, Kazakhstan

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 21, 2015
Enrollment StartJan 1, 2003
Primary CompletionDec 1, 2008
Study CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 10.9 years ago

Interventions

Xenical, Pionorm, Diroton, Diltiazem, Atorvastatindrug

Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day

"Analimentary detoxication"dietary

Vegetable and salt diet